Seelos therapeutics receives european orphan drug designation for sls-005 (trehalose) in amyotrophic lateral sclerosis (als)

New york, may 27, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received european orphan drug designation for sls-005 in amyotrophic lateral sclerosis (als) from the european medicines agency (ema) committee for orphan medicinal products (comp). under orphan designation in the european union (eu), seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity.
SEEL Ratings Summary
SEEL Quant Ranking